Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

C L M Krieckaert; S C Nair; M T Nurmohamed; C J J van Dongen; W F Lems; F P J G Lafeber; J W J Bijlsma; H Koffijberg; G Wolbink; P M J Welsing

doi:10.1136/annrheumdis-2013-204101

Article info

Clinical and epidemiological research

Extended report

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

Authors

C L M Krieckaert Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands PubMed articles Google scholar articles
S C Nair Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articles Google scholar articles
M T Nurmohamed Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands PubMed articles Google scholar articles
C J J van Dongen Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands PubMed articles Google scholar articles
W F Lems Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands PubMed articles Google scholar articles
F P J G Lafeber Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articles Google scholar articles
J W J Bijlsma Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articles Google scholar articles
H Koffijberg Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articles Google scholar articles
G Wolbink Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands PubMed articles Google scholar articles
P M J Welsing Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands PubMed articles Google scholar articles

Correspondence to C L M Krieckaert, Jan van Breemen Research Institute | Reade, PO Box 58271, Amsterdam 1040 HG, The Netherlands; c.krieckaert{at}reade.nl

View Full Text

Citation

Krieckaert CLM, Nair SC, Nurmohamed MT, et al

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

Annals of the Rheumatic Diseases 2015;74:361-368.

Publication history

Received June 10, 2013
Revised August 27, 2013
Accepted November 3, 2013
First published November 21, 2013.

Online issue publication

January 07, 2015

Article Versions

Previous version (21 November 2013).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password